Mink therapeutics to participate in september investor conferences

New york, aug. 24, 2023 (globe newswire) -- mink therapeutics (nasdaq: inkt), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced that dr. jennifer buell, chief executive officer and president, will participate in the following upcoming investor conferences:
INKT Ratings Summary
INKT Quant Ranking